I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
MINERVA UROLOGICA E NEFROLOGICA
Rivista di Nefrologia e Urologia
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Minerva Urologica e Nefrologica 2016 Sep 28
Basic methods for the assessment of the health related quality of life in uro-oncological patients
Roman SOSNOWSKI 1, Marta KULPA 2, Mariola KOSOWICZ 2, Fabrizio PRESICCE 3, Francesco PORPIGLIA 4, Andrea TUBARO 3, Cosimo DE NUNZIO 3, Tomasz DEMKOW 1 ✉
1 Department of Uro-Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 2 Department of Psycho-Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 3 Department of Urology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, Italy; 4 Division of Urology, Department of Oncology, University of Turin, Turin, Italy
BACKGROUND: The evaluation of patients' expectations and quality of life in uro-oncology is considered an important outcome of treatment efficacy and satisfaction. Aim of this systematic review was to evaluate the most frequently adopted tools in uro-oncology to assess Health Related Quality of Life (HRQoL).
EVIDENCE ACQUISITION: A systematic literature search until October 2015 was performed on MEDLINE, Cochrane Library, PubMed combining the following terms: “quality of life”, “health related quality of life”, “kidney cancer”, “bladder cancer”, “prostate cancer”. Additional references were obtained from the reference list of full-text manuscripts. Data were synthesized using meta-analytic methods conformed to the PRISMA statement.
EVIDENCE SYNTHESIS: HRQoL is a fundamental step in evaluating treatment outcome in patients with urological cancers. HRQoL is mostly measured through several questionnaires, which are generally categorised in generic questionnaires, exploring the patient’s well-being en bloc; specific questionnaires, assessing each single domain of health status; and uro-oncological specific questionnaires, mainly characterised by a modular approach. Although different questionnaires have been proposed and validated, the standard method to be adopted in urology is far from the solution and further studies should investigate the strength and weakness of the different questionnaires.
CONCLUSIONS: HRQoL questionnaires should become a standard method to evaluate medical/surgical outcomes in uro-oncology. Their implementation may significantly improve patients’ satisfaction and help physicians in the decision-making process and possibly reduce health care costs.